About us

About us

The Artificial Heart Frontiers Program presents a powerful, exciting opportunity from which to deliver urgently needed solutions, focussed on the application of mechanical circulatory support (MCS) devices, for people suffering from untreatable forms of advanced heart failure.

We are a multidisciplinary consortium that applies cutting-edge technologies to transform the healthcare of people with heart failure. We are committed to developing game-changing innovative medical devices that will improve and save lives.

Revolutionising heart failure therapies

The Artificial Heart Frontiers Program is developing a suite of next-generation devices to support all heart failure patients. We have partnered with BiVACOR Pty Ltd to assist in the commercialisation of their Australian-invented total artificial heart (TAH), a complete long-term replacement of the native heart. BiVACOR’s technology will also be leveraged to develop a series of next-generation devices for the treatment of segments of heart failure patients that now have few or no treatment options.

The devices will save the lives and improve the quality of life of many of the 300,000 Australians, and millions worldwide, now living with significant physical impairment due to heart failure. In the process, we have a unique opportunity to build a world-leading domestic cardiovascular device industry supported by Australia’s excellent science, research, and clinical expertise.